APPSC Group 1 Prelims 2024 Paper 2 · Question 66

Question 66 of the APPSC Group-I Prelims 2024 Paper II (17 March 2024). Try it first, then open the answer and explanation.

1. Prelims 2024 · P-II · Q66 · Science & Technology · Biotechnology & Health

   Identify India's first indigenously developed CAR-T cell therapy for which Central Drugs Standard Control Organization (CDSCO) granted market approval :

   1. NexCAR19
   2. TECARTUS
   3. IND YESCARTA
   4. BREYANZI-BH

   కేంద్ర ఔషధ ప్రమాణాల నియంత్రణ సంస్థ (CDSCO), మార్కెట్ ఆమోదం పొందిన భారతదేశం యొక్క మొట్టమొదటి దేశీయంగా అభివృద్ధి చేయబడిన CAR-T సెల్ థెరపీని గుర్తించండి :

   1. NexCAR19
   2. TECARTUS
   3. IND YESCARTA
   4. BREYANZI-BH
   Show answer

   Answer: (1) NexCAR19

   సమాధానం: (1) NexCAR19

   NexCAR19 was developed by ImmunoACT, a company incubated at IIT Bombay, with Tata Memorial Centre. In 2023 it became the first home-grown CAR-T cell therapy approved by CDSCO, while Tecartus, Yescarta and Breyanzi are foreign CAR-T products.

Answer it in the practice appMake a topic-wise quiz